RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its ...

“We look forward to continued research in hypovascular tumors using minimally invasive procedures and are also working on a radiation sub-study. With continued investigation, we believe TAMP has ...

The tumour microenvironment in PDA is characterised by hypovascularity and extensive deposits of extracellular matrix components. The desmoplastic and hypovascular nature of PDA contributes to its ...

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote tumour progression, ...